Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Petros Pharmaceuticals (PTPI)
NASDAQ:PTPI
RESEARCH TOOLSreports
Holding PTPI?
Track your performance easily
PTPI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.22 - $2.27
Previous Close$0.26
Volume260.94K
Average Volume (3M)177.76K
Market Cap
$2.59M
Enterprise Value$5.95M
Total Cash (Recent Filing)$3.89M
Total Debt (Recent Filing)$7.25M
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Nov 14, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.21
Shares Outstanding10,014,872
10 Day Avg. Volume185,246
30 Day Avg. Volume177,762
Standard Deviation0.42
R-Squared0.06
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.81
Price to Sales (P/S)0.65
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.98
Enterprise Value/Gross Profit1.42
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$1.00Price Target Upside286.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Petros Pharmaceuticals News
PremiumCompany Announcements
Petros Pharmaceuticals Amends President’s Employment Terms
PremiumCompany Announcements
Board Reshuffle at Petros Pharmaceuticals Following Resignations
Bulls Say, Bears Say
Bulls Say
Positive Study ResultsConsistent success in studies, including a >500 patient study, suggests that Petros' technology works as intended, effectively selecting against concomitant nitrate use.
Regulatory ClarityThe finalized ACNU pathway should further de-risk development and provide greater clarity in terms of regulatory standards, study designs, and development costs.
Technology EffectivenessPetros' Web App Technology has shown statistically significantly higher rates of correct self-selection for erectile dysfunction compared to the traditional Drug Facts Label.
Bears Say
Financing And DilutionAdditional financing will be necessary to continue operations, potentially leading to more share dilution.
Operational CostsOperating expenses were higher than expected due to increased SG&A and R&D costs.
Revenue DeclineRevenue dropped by 27%, indicating significant financial challenges.
---
Ownership Overview
0.86% Insiders
0.76% Mutual Funds
0.71% Other Institutional Investors
97.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PTPI FAQ
What was Petros Pharmaceuticals’s price range in the past 12 months?
Petros Pharmaceuticals lowest stock price was $0.22 and its highest was $2.27 in the past 12 months.
What is Petros Pharmaceuticals’s market cap?
Currently, no data Available
When is Petros Pharmaceuticals’s upcoming earnings report date?
Petros Pharmaceuticals’s upcoming earnings report date is Nov 14, 2023 which is 373 days ago.
How were Petros Pharmaceuticals’s earnings last quarter?
Petros Pharmaceuticals released its earnings results on Aug 15, 2023. The company reported -$1.203 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.203.
Is Petros Pharmaceuticals overvalued?
According to Wall Street analysts Petros Pharmaceuticals’s price is currently Undervalued.
Does Petros Pharmaceuticals pay dividends?
Petros Pharmaceuticals does not currently pay dividends.
What is Petros Pharmaceuticals’s EPS estimate?
Petros Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Petros Pharmaceuticals have?
Petros Pharmaceuticals has 10,014,872 shares outstanding.
What happened to Petros Pharmaceuticals’s price movement after its last earnings report?
Petros Pharmaceuticals reported an EPS of -$1.203 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.787%.
Which hedge fund is a major shareholder of Petros Pharmaceuticals?
Currently, no hedge funds are holding shares in PTPI
---
Petros Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-46.82%
Trailing 12-Months
Company Description
Petros Pharmaceuticals
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including endothelial dysfunction, psychosexual and psychosocial ailments, peyronie's disease, hormone health and substance use disorders.
---
PTPI Stock 12 Month Forecast
Average Price Target
$1.00
▲(286.10% Upside)
Technical Analysis
Best Analysts Covering PTPI
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-49.51%
reiterated a buy rating 2 months ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -49.51% per trade.
---